X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Through the acquisition, Almirall get exclusive rights to commercialize the Prometax (rivastigmine hydrogen tartrate), a multi-day transdermal patch for the treatment of Alzheimer’s disease.
Lead Product(s): Rivastigmine Tartrate
Therapeutic Area: Neurology Product Name: Prometax
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Almirall
Deal Size: $64.2 million Upfront Cash: $48.1 million
Deal Type: Acquisition September 04, 2023
Details:
Exelon (rivastigmine tartrate) is an oral acetylcholinesterase inhibitor, which is approved for the treatment of mild to moderately severe dementia in people with Alzheimer's disease and Parkinson's disease..
Lead Product(s): Rivastigmine Tartrate
Therapeutic Area: Neurology Product Name: Exelon
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2022
Details:
Exelon (rivastigmine tartrate) is an oral acetylcholinesterase inhibitor, which is approved for the treatment of mild to moderately severe dementia in people with Alzheimer's disease and Parkinson's disease..
Lead Product(s): Rivastigmine Tartrate
Therapeutic Area: Neurology Product Name: Exelon
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
Knight Therapeutics has acquired exclusive rights to manufacture, market and sell Exelon® (rivastigmine Patch, Capsules and Solution) in Canada and Latin America, as well as an exclusive license to use the intellectual property and the Exelon trademark, from Novartis.
Lead Product(s): Rivastigmine Tartrate
Therapeutic Area: Neurology Product Name: Exelon
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Knight Therapeutics
Deal Size: $180.0 million Upfront Cash: $168.0 million
Deal Type: Acquisition May 26, 2021
Details:
Exelon (rivastigmine) is a prescription product that was first approved in 1997 and is currently registered and sold in approximately 90 countries. Exelon is indicated for the symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's disease.
Lead Product(s): Rivastigmine Tartrate
Therapeutic Area: Neurology Product Name: Exelon
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Knight Therapeutics
Deal Size: $180.0 million Upfront Cash: $168.0 million
Deal Type: Acquisition April 23, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
